-
Mitsubishi Tanabe Pharma Canada Announces New Leadership
Mitsubishi Tanabe Pharma Canada Announces...
Read More
April 3, 2023
-
Mitsubishi Tanabe Pharma Canada Receives Engagement Letter from pan-Canadian Pharmaceutical Alliance for prRADICAVA® Oral Suspension
TORONTO, Canada – March 30, 2023 –...
Read More
March 30, 2023
-
Mitsubishi Tanabe Pharma Canada Announces prRADICAVA® (Edaravone) Oral Suspension Is Now Available in Canada for the Treatment of Patients with ALS
Mitsubishi Tanabe Pharma Canada, Inc....
Read More
February 10, 2023
-
prRADICAVA® (Edaravone) Oral Suspension Receives Positive Recommendation from CADTH for the Treatment of Patients with ALS
Mitsubishi Tanabe Pharma Canada, Inc....
Read More
January 18, 2023
-
prRADICAVA® (Edaravone) Oral Suspension Receives Positive Recommendation from INESSS for the Treatment of Patients With ALS
(MTPA) is pleased to announce a positive...
Read More
December 19, 2022
-
Mitsubishi Tanabe Pharma Canada Announces Canadian Authorization of prRADICAVA® (Edaravone) Oral Suspension for the Treatment of Patients with ALS
Comprehensive clinical development program...
Read More
November 9, 2022
-
Mitsubishi Tanabe Pharma Canada Announces Publication of Real-World Data for Radicava® (Edaravone)
TORONTO, ON August 15, 2022 – Mitsubishi...
Read More
August 15, 2022
-
Health Canada Accepts SNDS Filing and Grants Priority Review for Oral Edaravone Formulation for the Treatment of ALS
TORONTO, Canada - May 13, 2022 –...
Read More
May 13, 2022
-
Mitsubishi Tanabe Pharma Canada Announces that Prince Edward Island has Added the Company’s Treatment for Amyotrophic Lateral Sclerosis (ALS) to its Provincial Drug Formulary
TORONTO, November 23, 2021 - Mitsubishi...
Read More
November 23, 2021
-
Mitsubishi Tanabe Pharma Canada Announces That Treatment for Amyotrophic Lateral Sclerosis (ALS) Is Now Available Through Newfoundland and Labrador Prescription Drug Program
TORONTO, March 10, 2021 - Mitsubishi...
Read More
March 10, 2021
-
MTP-CA Applauds the Release of Canada’s First ALS Management Guidelines
Mitsubishi Tanabe Pharma Canada (MTP-CA)...
Read More
November 18, 2020
-
Mitsubishi Tanabe Pharma Canada Announces Treatment for Amyotrophic Lateral Sclerosis (ALS) Now Eligible for Coverage Through Veterans Affairs Canada and Indigenous Services Canada
TORONTO, September 21, 2020 - Mitsubishi...
Read More
September 21, 2020
-
Mitsubishi Tanabe Pharma Canada Announces That Treatment for Amyotrophic Lateral Sclerosis (ALS) Has Been Added to British Columbia PharmaCare Formulary
TORONTO, August 19, 2020 - Mitsubishi...
Read More
August 19, 2020
-
Mitsubishi Tanabe Pharma Canada Announces That Nova Scotia has Added the Company’s Treatment for Amyotrophic Lateral Sclerosis (ALS) to its Provincial Drug Plan Formulary
TORONTO, July 7, 2020 - Mitsubishi Tanabe...
Read More
July 7, 2020
-
Mitsubishi Tanabe Pharma Canada Announces That Manitoba has Added the Company’s Treatment for Amyotrophic Lateral Sclerosis (ALS) to its Provincial Drug Plan Formulary
TORONTO, June 30, 2020 - Mitsubishi Tanabe...
Read More
June 30, 2020
-
Mitsubishi Tanabe Pharma Canada Announces That Saskatchewan has Added the Company’s Treatment for Amyotrophic Lateral Sclerosis (ALS) to its Provincial Drug Plan Formulary
TORONTO, June 30, 2020 - Mitsubishi Tanabe...
Read More
June 30, 2020
-
Mitsubishi Tanabe Pharma Canada Announces That Company’s Treatment for Amyotrophic Lateral Sclerosis (ALS) Has Been Added to the Provincial Drug Plan in New Brunswick
TORONTO, June 18, 2020 - Mitsubishi Tanabe...
Read More
June 18, 2020
-
Mitsubishi Tanabe Pharma Canada Announces that Company’s Treatment for Amyotrophic Lateral Sclerosis (ALS) Has Been Added to the Provincial Drug Plan in Alberta
Mitsubishi Tanabe Pharma Canada, Inc....
Read More
June 1, 2020
-
Mitsubishi Tanabe Pharma Canada Announces that Company’s Treatment for Amyotrophic Lateral Sclerosis (ALS) Has Been Added to the Provincial Drug Plan in Ontario
Mitsubishi Tanabe Pharma Canada, Inc....
Read More
May 28, 2020
-
Mitsubishi Tanabe Pharma Canada Announces that Company’s Treatment for Amyotrophic Lateral Sclerosis (ALS) Has Been Added to the Provincial Drug Plan in Quebec
Mitsubishi Tanabe Pharma Canada, Inc....
Read More
April 29, 2020
-
Mitsubishi Tanabe Pharma Canada Concludes Letter of Intent with Pan-Canadian Pharmaceutical Alliance for RADICAVA® (edaravone)
TORONTO, April 22, 2020 - Mitsubishi...
Read More
April 22, 2020
-
MTP-CA’s Response to COVID-19
Mitsubishi Tanabe Pharma Canada, Inc....
Read More
March 20, 2020
-
Mitsubishi Tanabe Pharma Canada Announces Availability of RADICAVA® (edaravone) for Amyotrophic Lateral Sclerosis
Mitsubishi Tanabe Pharma Canada, Inc....
Read More
November 5, 2019
-
Update on Canadian Product Availability
Mitsubishi Tanabe Pharma Canada (MTP-CA)...
Read More
October 23, 2019
-
Mitsubishi Tanabe Pharma Canada Announces Canadian Authorization of RADICAVA™ (Edaravone) to Treat ALS
TORONTO, October 4, 2018 -- Mitsubishi...
Read More
October 4, 2018
-
New Country Manager Brings Significant Business Leadership and Healthcare Expertise to Mitsubishi Tanabe Pharma Canada, Inc.
TORONTO, September 28, 2018 – Mitsubishi...
Read More
September 28, 2018